

**GYN Symposium -“Neoadjuvant Chemotherapy for Ovarian Cancer  
– Clinical Considerations and Research Opportunities”  
February 5, 2015 (NRG Oncology Semi-Annual Meeting)  
Manchester Grand Hyatt, San Diego, California**

<b>Program Chair</b>	Ronald D. Alvarez, MD <i>University of Alabama at Birmingham</i>	<b>Planning Committee</b>	Neil Horowitz, MD <i>Dana Farber Partners Cancer Center</i> William P. Tew, MD <i>Memorial Sloan Kettering Cancer Center</i>
----------------------	---	---------------------------	---

**Presentation Agenda**

<b>Time</b>	<b>TOPIC</b>	<b>SPEAKER/MODERATOR</b>
<b>7:00 AM</b>	<b>REGISTRATION</b>	
<b>8:00 AM</b>	<b>WELCOME</b>	<b>Program Chair</b>
<b>8:05-9:30</b>	<b>SESSION I: Surgery or NACT in Ovarian Cancer: Factoring in Age, Functional Status and Comorbidity</b>	<b>Moderator: William P. Tew, MD</b>
<b>8:05- 8:25</b>	Overview of NACT for Ovarian Cancer	Deborah Armstrong, MD
<b>8:25 – 8:45</b>	Surgical Considerations in the Elderly	Kathleen Moore, MD
<b>8:45 – 9:05</b>	Preoperative Assessment: Predicting Complications	William P. Tew, MD
<b>9:05 – 9:25</b>	Ovarian Cancer in the Elderly: GOG 273 and Future Steps	Vivian von Gruenigen, MD
<b>9:30 – 10:00</b>	<b>BREAK</b>	
<b>10:05-11:30</b>	<b>SESSION II: Assessing Resectability as a Guide to Choosing NACT or Primary Cytoreduction</b>	<b>Moderator: Neil Horowitz, MD</b>
<b>10:05 – 10:25</b>	Use of imaging and tumor markers to predict suboptimal cytoreduction	Dennis Chi, MD
<b>10:25 – 10:45</b>	Modeling to predict complete cytoreduction – can it be done?	Neil Horowitz, MD
<b>10:45 – 11:05</b>	Gene expression signatures to predict debulking status	Michael Birrer, MD, Ph.D.
<b>11:05 – 11:25</b>	Molecular predictors of residual disease after cytoreduction	Anil Sood, MD
<b>11:30 -11:45</b>	<b>YIA presentations – <i>Role of CT scans in assessment of response to treatment in GOG ovarian cancer trials: is CA-125 and physical exam good enough</i></b>	Whitney Graybill, MD
<b>11:45-12:00</b>	<b><i>Examining the paradigm for testing systemic therapies in recurrent and advanced cervical cancers</i></b>	Lilian Gien, MD
<b>12:00-1:00</b>	<b>LUNCH</b>	
<b>1:00-2:30</b>	<b>SESSION III: NACT in Ovarian Cancer: Identifying and Seizing the Research Opportunities</b>	<b>Moderator: Ronald D. Alvarez, MD</b>
<b>1:00 – 1:20</b>	The MATCH (Molecular Analysis for Therapy Choice) Trial	Barbara Conley, MD

<b>1:20 – 1:40</b>	Randomized Phase II Study of Novel Targeted Agents in the Neoadjuvant Therapy Setting	Robert Burger, MD
<b>1:40– 2:00</b>	Assessing Biomarkers in NACT Trials	Michael Bookman, MD
<b>2:00 – 2:20</b>	Statistical Considerations in NACT Trials	Michael Sill, PhD
<b>2:20 – 2:30</b>	Panel discussion	

#### **PROGRAM DESCRIPTION:**

The GOG Foundation, Inc. will have a winter 2015 Educational Symposium titled “***Neoadjuvant Chemotherapy for Ovarian Cancer – Clinical Considerations and Research Opportunities***” with noted Oncologists and Scientists serving as speakers and moderators. The targeted audiences are members and non-members of the NRG research teams to include: Gynecologic Oncologists, Medical Oncologists, Radiation Oncologists, Pathologists, and other MDs engaged in oncology research and/or clinical practice; Oncology Nurses, Nurse-practitioners, and other interested Allied Health professionals. The speakers will focus their presentations on evidence regarding NACT in advanced ovarian cancer, how to more formally assess medical and functional status and resectability when making a decision regarding NACT versus primary debulking in a patient with presumed advanced ovarian cancer. Lastly, speakers will discuss ongoing trials incorporating assessment of novel targeted agents in NACT clinical trials currently in development.

#### **LEARNING OBJECTIVES:**

1. To recognize the current evidence regarding NACT in advanced ovarian cancer.
2. To apply current strategies to assess functional status and co-morbidities in patients with advanced ovarian cancer and utilize this information to inform decision regarding NACT or primary debulking in advanced ovarian cancer.
3. To outline the evidence regarding how various imaging and biomarker strategies can be utilized to inform decision regarding NACT or primary debulking in advanced ovarian cancer.
4. To explain how future trials incorporating NACT strategies can be utilized to identify key biologic processes in ovarian cancer and how targeted therapeutics might affect these processes.

#### **GOG COMMITTEE ON EDUCATIONAL ACTIVITIES**

Ronald Alvarez, MD (Committee Chair) University of Alabama at Birmingham Birmingham, AL	Neil Horowitz, MD Brigham and Women’s Hospital Dana Farber Partners Cancer Care Boston, MA
Frederick Stehman, MD (Co-Chairman) Indiana University School of Medicine Indianapolis, IN	William Tew, MD Memorial Sloan Kettering Cancer Center New York, NY
Sarah Bernstein, RN, MS, AOCN Walter Reed National Military Med Ctr. Bethesda, MD	Michelle N. Small, BSHA (Staff) Assoc. Director, Education Programs & CME Compliance GOG Education Program msmall@gog.org
John Farley, MD St. Joseph Hospital and Medical Center Phoenix, AZ	Jill Reese (Staff) CME Administrator GOG Education Program jreese@gog.org